Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
...Published in Blood Advances
Development of luspatercept to treat ineffective erythropoiesis
Published in Blood Advances
Platelets as drivers of ischemia/reperfusion injury after stroke
Published in Blood Advances
Ischemic stroke is a leading cause of morbidity and mortality worldwide and, despite reperfusion either via thrombolysis or thrombectomy, stroke patients often suffer from lifelong disabilities. These persistent neurological deficits may be improved by treating the ischemia/reperfusion (I/R) injury that occurs following ischemic stroke. There are c...
Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis
...Published in Blood Advances
Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia
...Published in Blood Advances
Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic ure...
...Published in Blood Advances
Deregulated expression of circular RNAs in acute myeloid leukemia
...Published in Blood Advances
Population pharmacokinetics of the von Willebrand factor–factor VIII interaction in patients with von Willebrand disease...
...Published in Blood Advances
Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines
...Published in Blood Advances
Heterogeneous NLRP3 inflammasome signature in circulating myeloid cells as a biomarker of COVID-19 severity
...Published in Blood Advances
